medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Genetics of Height and Risk of Atrial Fibrillation: A Mendelian
Randomization Study
Michael G. Levin, MD 1,2,3; Renae Judy, MS 4; Dipender Gill, MBBS 5; Marijana Vujkovic, PhD,
MSCE2,3; Regeneron Genetics Center 6; Matthew C. Hyman, MD, PhD 1,2; Saman Nazarian,
MD, PhD 1,2; Daniel J. Rader, MD 2,7,8; Benjamin F. Voight, PhD 7,8,9; Scott M. Damrauer, MD 3,4
1

Division of Cardiovascular Medicine, University of Pennsylvania Perelman School of
Medicine, Philadelphia, PA
2Department of Medicine, University of Pennsylvania Perelman School of Medicine,
Philadelphia, PA
3Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
4Department of Surgery, University of Pennsylvania Perelman School of Medicine,
Philadelphia, PA
5Department of Epidemiology and Biostatistics, School of Public Health, Imperial College
London, United Kingdom
6Regeneron Genetics Center, Tarrytown, NY
7Department of Genetics, University of Pennsylvania Perelman School of Medicine,
Philadelphia, PA
8Institute for Translational Medicine and Therapeutics, University of Pennsylvania Perelman
School of Medicine, Philadelphia, PA
9Department of Systems Pharmacology and Translational Therapeutics, University of
Pennsylvania Perelman School of Medicine, Philadelphia, PA

Word Count: 3496
Corresponding Author:
Scott M. Damrauer
3400 Spruce Street, Silverstein 4
Philadelphia PA 19104
Phone: 215-615-1698
damrauer@upenn.edu

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

ABSTRACT
Objective: To determine whether height has a causal effect on risk of atrial fibrillation
Design: Mendelian randomization study
Setting: Genome-wide association studies of height and atrial fibrillation; Penn Medicine
Biobank
Participants: Multiethnic (predominantly European ancestry) participants in genome-wide
association studies of height (693,529 individuals) and atrial fibrillation (65,446 cases and
522,744 controls); 7,023 Penn Medicine Biobank participants of European ancestry
Exposures: Height, cardiometabolic risk factors for atrial fibrillation, and randomly allocated
genetic variants strongly associated with these traits
Main outcome measure: Risk of atrial fibrillation (measured in odds ratio)
Results: At the population level, a 1 standard deviation increase in genetically-predicted height
was associated with increased odds of AF (Odds ratio [OR] 1.34; 95% Confidence Interval [CI]
1.29 to 1.40; p = 5x10-42). These findings remained consistent in sensitivity analyses that were
robust to the presence of pleiotropic variants. Results from analyses considering individualparticipant data were similar, even after adjustment for clinical covariates, including left atrial
size.
Conclusions: Genetically predicted height is a positive causal risk factor for AF. This finding
raises the possibility of investigating height/growth-related pathways as a means for gaining
novel mechanistic insights to atrial fibrillation, as well as incorporating height into population
screening strategies for atrial fibrillation.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

INTRODUCTION
Atrial fibrillation is a common cardiac arrhythmia, with a population prevalence of 0.5%,
affecting more than 33 million individuals worldwide.[1] A number of risk factors are associated
with atrial fibrillation, including chronic diseases like chronic kidney disease, heart failure,
hyperthyroidism, obesity, obstructive sleep apnea, sleep apnea, and valvular heart disease, as
well as cardiac surgery, smoking, and anthropometric factors.[2â€“5] Recent studies have
identified both common and rare genetic variants at more than 100 independent loci
contributing to the incidence of atrial fibrillation, and heritability is estimated at 20%.[6â€“8] Even
with treatment, affected individuals are at risk of cardioembolic stroke, heart failure, and
death.[2]
Height has been identified as a risk factor for a number of cardiometabolic diseases,
including coronary artery disease, atrial fibrillation, and venous thromboembolism.[9,10] The
relationship between height and atrial fibrillation in particular has been identified in large
observational studies, with greater height strongly associated with increased risk of atrial
fibrillation.[4,11â€“18] These studies are limited in assessing the causality and potential
mediators of confounders of this association by their observational design, and randomized
controlled trials of anthropometric traits are not feasible. Although a number of factors
influence height including childhood illness/development, diet/nutrition, and socioeconomic
status, height has a strong genetic component. Large genome-wide association studies have
provided heritability estimates of 60-70%, and identified more than 700 independent loci that
contribute to height.[19â€“22]

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

In the current study, we utilize human genetic data within the Mendelian randomization
framework to evaluate a potential causal association between height and atrial fibrillation.
Mendelian randomization leverages the random assortment of genetic variants during meiosis
as instrumental variables to estimate the causal role between a trait and an outcome of
interest. Here, we use summary data from large multiethnic GWAS of height (N ~ 693,529
individuals) and atrial fibrillation (65,446 cases and 522,744 controls) to estimate the effect of
genetically-predicted height on risk of atrial fibrillation.[7,19] We then use participant level data
from the Penn Medicine Biobank within the observational phenome-wide association study
(PheWAS) framework to identify other clinical associations with height, and within the singlesample MR framework to further assess the impact of height on atrial fibrillation after
adjustment for clinical risk factors.

MATERIALS AND METHODS
Mendelian Randomization Analysis
Summary-level data for GWAS of height and atrial fibrillation were obtained. Twosample mendelian randomization, using summary-level data, was performed using the
TwoSampleMR package in R.[23] Using variants associated with height at genome-wide
significance (p < 5Ã—10-8), SNPs were harmonized with the variants from the Roselli et al. (2018)
atrial fibrillation GWAS, and LD-pruned (distance threshold = 10,000kb, r2 = 0.001) using the
clump_data command in the TwoSampleMR package in R, identifying a final set of 707
independent SNPs to use as a genetic instrument for height, which accounted for 11.2% of the
variability in height (Supplemental Table 1). Inverse variance weighted two-sample Mendelian

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

randomization was used as the primary analysis, with weighted median, MR-Egger, and MRPRESSO performed as sensitivity analyses to account for potential violations of the instrumental
variable assumptions.[24] Further sensitivity analysis was performed using a genetic instrument
for height constructed excluding any SNPs nominally (p < 0.05) associated with coronary artery
disease, HDL, LDL, total cholesterol, triglycerides, fasting glucose, fasting insulin, diabetes, BMI,
waist-to-hip ratio, and systolic blood pressure, all identified using the MR-base database.[25â€“
28]
For each variant included in the genetic instruments, variance (R2) was calculated using
the formula ð‘…2 = 2 Ã— ð‘€ð´ð¹ Ã— (1 âˆ’ ð‘€ð´ð¹) Ã— ð‘ð‘’ð‘¡ð‘Ž2 (where MAF represents the effect allelefrequency and beta represents the effect estimate of the genetic variant in the exposure
GWAS). F-statistics were then calculated for each variant using the formula ð¹ =

ð‘…2 Ã—(ð‘âˆ’2)
1âˆ’ð‘…2

(where R2 represented the variance in exposure explained by the genetic variant, and N
represents the number of individuals in the exposure GWAS) to assess the strength of the
selected instruments.[29]
To account for the possibility that the restrictive genetic instrument may introduce
collider or ascertainment bias by conditioning on associated traits, multivariable MR was
performed using the TwoSampleMR package in R. This method allows the direct effects of
multiple traits on an outcome to be determined jointly. The effect of height on atrial fibrillation
was estimated in analyses that individually adjusted for potential confounders including
coronary artery disease, HDL, LDL, total cholesterol, triglycerides, fasting glucose, fasting
insulin, diabetes, BMI, waist-to-hip ratio, and systolic blood pressure, using genetic variants
obtained from MR-base as above. Potential confounders that had significant (p<0.05) direct

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

effects on atrial fibrillation in the individual multivariable models were then combined in a final
model to jointly estimate their direct effects on atrial fibrillation.
Bidirectional MR was performed to assess for the possibility of reverse causality. A
genetic instrument for atrial fibrillation containing 73 independent, genome-wide significant
variants was constructed using the same methods as for the height instrument. Inversevariance weighted, weighted median, and MR-Egger analyses were performed.
Individual-level MR was performed using the logistic control function estimator for the
6337 individuals with available height, genotype, and clinical covariate information.[30] The
instrumental variable was a standardized genetic risk score for height, computed from
independent, genome-wide significant variants, weighted by effect on height in the GIANT
GWAS (see Height Genetic Risk Score above). Of the 707 genetic variants included in the main
instrumental variable for height in the two-sample MR analysis, 695 were available for use in
the individual-level analysis (Supplemental Table 3). In the first stage of the two-stage process,
a linear regression was conducted with standardized height as the dependent variable, and the
standardized genetic risk score for height as the independent variable. In the second stage, a
logistic regression model with robust standard errors was fit, incorporating both the residuals
from the first stage and scaled height, with atrial fibrillation as the outcome. In additional
models, the second stage was adjusted for clinical diagnoses and left atrial size. Sensitivity
analysis was performed including only individuals who had available echocardiographic data.

Penn Medicine Biobank

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

The Penn Medicine Biobank is a longitudinal genomics and precision medicine study in
which participants consent to linkage of genomic information and biospecimens to the
electronic health record. More than 60,000 individuals are currently enrolled. This study
included 7,023 individuals of European ancestry (genetically determined) who underwent
genotyping and had available electronic health record data. For individual-level analyses in the
Penn Medicine Biobank, continuous demographic variables were summarized by median and
interquartile range, with categorical variable summarized by count and group-percent.
Wilcoxon rank sum and Fisherâ€™s exact tests, respectively, were used to assess for significant
differences between groups.

Phenotype Ascertainment
For individual level analyses in Penn Medicine Biobank, phenotypes were determined by
querying the electronic health record. International Classification of Diseases (ICD) 9/10 and
Current Procedural Terminology (CPT) codes, in addition to laboratory measurements and vital
signs, were used to identify height, weight, BMI, smoking status, diagnoses of heart failure,
hypertension, diabetes mellitus, chronic kidney disease, sleep apnea, stroke, thyroid disease,
valvular heart disease, and cardiac surgery. Of the 7,420 individuals with high quality genotype
data, complete phenotypes could be determined for 7,023 individuals. Transthoracic
echocardiogram data was available for 2805 individuals. Left atrial size measured in the
parasternal long axis view was extracted, and for individuals with more than one measure
available the median value was used. Data was extracted as of January 2017. (Supplemental
Methods).

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Height Genetic Risk Score
A standardized, weighted genetic risk score (GRS) for height was calculated for each
individual in the Penn Medicine Biobank using imputed dosage information in an additive
model, weighted by the effect size of each independent (distance threshold = 10,000kb, r 2 =
0.001), genome-wide significant (p < 5Ã—10-8) variant from the Yengo et al. (2018) GWAS of
height, using the clump_data command in the TwoSampleMR package in R.[19] Scores were
standardized, centered to mean = 0 and scaled.

Phenome-wide association study
Phenome-wide association studies were performed to identify clinical diagnoses
associated both measured height (N = 6759) and the height genetic risk score (N = 7023), using
the default setting of the PheWAS package in R.[31] Briefly, international classification disease
codes obtained from the electronic health record were mapped to â€œPhecodes,â€ and individuals
were assigned to case/control status or excluded using default mapping parameters.
Association between height/height GRS and phenotypes was tested using logistic regression,
adjusted for age, age2, sex, and 10 genetic principal components.

Statistical Analysis
All statistical analyses were performed using R version 3.5.1.[32] For statistical analyses p<0.05
was considered statistically significant.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

RESULTS
Demographics
Individual-level analysis focused on 7023 European Ancestry individuals from the Penn
Medicine Biobank with available genotype data linked to the electronic health record.
Individuals with atrial fibrillation were older (68 vs. 60 years; p < 0.001) than individuals without
atrial fibrillation. Individuals with atrial fibrillation were taller (68 vs. 67 inches; p < 0.001), and
significantly more likely to have been diagnosed with chronic kidney disease, heart failure,
hyperlipidemia, hypertension, prior cardiac surgery, sleep apnea, smoking, stroke, thyroid
disease, or valvular heart disease, compared to individuals without atrial fibrillation (Table 1).

Phenome-wide association studies of Height and Height GRS
To determine the association between genetically-predicted height and clinical
diagnoses, we first constructed a genetic risk score for height using weights derived from the
2018 UK Biobank/GIANT height GWAS meta-analysis. Phenome-wide association studies were
performed to identify clinical diagnoses associated with both measured height and the height
genetic risk score across the Penn Medicine Biobank. Each 1 standard deviation increase in
measured height was associated with increased risk of atrial fibrillation (OR 1.1; p = 5.9Ã—10-17),
and decreased risk of coronary atherosclerosis (OR 0.90; p = 3.4Ã—10-20) and ischemic heart
disease (OR 0.91; p = 1Ã—10-18). Each 1 standard deviation increase in height PRS was associated
with increased risk of atrial fibrillation and flutter (OR 1.15; p = 6Ã—10-6) (Figure 1).

Population-Level Mendelian Randomization

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

To further characterize the relationship between increasing height and risk of atrial
fibrillation, we constructed a genetic instrument for height using 707 independent SNPs
associated with height at a genome-wide level of significance (p < 5Ã—10-8), which accounted for
11.2% of the variability in height (Supplemental Table 1). The mean F-statistic was 110 (range
22-948), suggesting the risk of weak-instrument bias was low.[33] . We performed two-sample
Mendelian randomization using summary statistics from a genome-wide association study of
atrial fibrillation including 65,446 atrial fibrillation cases and 522,744 controls. Inverse varianceweighted modeling identified a significant association between increasing height and atrial
fibrillation (OR 1.34; 95% CI 1.29 to 1.40; p = 5x10-42) (Figure 2). The intercept from Egger
regression was -0.001 (p = 0.13), thus not providing evidence for significant pleiotropic bias.
Similar estimates were obtained in sensitivity analyses from weighted median, MR-Egger, and
MR-PRESSO models.
An additional genetic instrument for height was constructed, excluding variants
nominally associated (p < 0.05) with potentially pleiotropic risk factors for atrial fibrillation. The
restrictive instrument consisted of 224 independent SNPs, in sum explaining 2.8% of the
variance in height (Supplemental Table 2). The mean F-statistic was 88 (range 22-867).
Mendelian randomization results using this restrictive genetic instrument were similar
(Supplemental Figure 1).
We next performed multivariable Mendelian randomization. Height remained
significantly associated with atrial fibrillation after adjustment for the effect of genetic variants
separately on each of coronary artery disease, HDL, LDL, total cholesterol, triglycerides, fasting
glucose, fasting insulin, diabetes, BMI, waist-to-hip ratio, and systolic blood pressure

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

(Supplemental Table 4). This analysis identified significant associations between BMI, systolic
blood pressure, total cholesterol, and coronary artery disease with atrial fibrillation after
adjustment for height. The effect of height on risk of atrial fibrillation was similar in models
accounting for these risk factors individually, and in a combined model jointly considering
genetic variants associated with height, BMI, systolic blood pressure, total cholesterol, and
coronary artery disease (Figure 3).
To assess for the possibility of reverse-causation, where genetic variants primarily
associated with increased risk of atrial fibrillation may represent invalid instruments for height,
a bi-directional multivariable analysis was performed. Using a genetic instrument including 73
independent, genome-wide significant variants associated with atrial fibrillation, there was no
evidence for a causal association with height (Supplemental Figure 2).

Individual-Level Mendelian Randomization
Individual-level Mendelian randomization was performed in Penn Medicine Biobank
participants to further assess the association between height and atrial fibrillation. Using the
height weighted genetic risk score as an instrumental variable, height was significantly
associated with atrial fibrillation (OR 1.69 per 1 standard deviation increase in height; 95% CI
1.54 to 2.19; p = 5Ã—10-4) after adjusting for age, sex, and 5 genetic principal components (Figure
4). Height remained associated with atrial fibrillation after adjustment for weight, hypertension,
coronary artery disease, heart failure, hyperlipidemia, diabetes, chronic kidney disease, sleep
apnea, stroke, hyperthyroidism, smoking, cardiac surgery, and valvular heart disease. After
further adjustment for left atrial size, height remained significantly associated with atrial

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

fibrillation (OR 1.76; 95% CI 1.43 to 2.17; p = 0.005). When individual-level MR was restricted to
the subset of individuals with complete data, the effect estimates were similar, with modest
attenuation with sequential adjustment for clinical risk factors and left atrial size (Supplemental
Figure 3).

DISCUSSION
In this study we used both population- and individual-level genetic information to test
the association between height and atrial fibrillation. At the population level, there was a
strong causal association between genetic determinants of height and risk of atrial fibrillation.
This finding was robust to multiple sensitivity analysis in the Mendelian randomization methods
and the genetic instrument for height. Observational analysis at the individual-level identified a
strong association between height and increased risk of atrial fibrillation, and decreased risk of
coronary artery disease. Using individual-level MR analysis, we found that the relationship
between height and atrial fibrillation appears to be independent from traditional clinical and
echocardiographic risk factors for atrial fibrillation.
Our findings are consistent with prior observational analyses that have identified height
as a risk factor for atrial fibrillation.[4,11â€“18] These studies, including a large Swedish national
cohort study of 1.5 million military conscripts recruited over the course of 28 years have
consistently identified a strong association between height and atrial fibrillation.[4]
Observational designs have limited these studies, due to the possibility of residual confounding.
The Helsinki Birth Cohort Study partially addressed this limitation by considering the effect of
maternal height on risk of atrial fibrillation in offspring, but was limited by a small, homogenous

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

sample.[34] We further build on those prior findings using the Mendelian randomization
framework, considering both summary-level and individual-level genetic data, leveraging
genetic variants associated with height and atrial fibrillation to provide a causal estimate for the
effect of increasing height on risk of atrial fibrillation. Our population-level Mendelian
randomization analysis reinforces a prior MR estimate for association between increasing
height and atrial fibrillation (OR 1.33; 95% CI 1.26 to 1.40) using updated GWAS summary
statistics for height and atrial fibrillation.[9] By leveraging large multiethnic studies of both
height and atrial fibrillation, we increase the generalizability of the prior MR findings, which
were limited only to white participants of the UK Biobank.
Several mechanisms have been proposed to explain the relationship between height
and atrial fibrillation. Increased left atrial size is correlated with height, and has been identified
as independent predictor of atrial fibrillation.[18,35â€“37] Consistent with findings from the
Cardiovascular Health Study, however, we found the effect of height on risk of atrial fibrillation
was not attenuated after adjustment for left atrial diameter.[14] It is possible that other, more
nuanced markers of left atrial structure and function that have been associated with severity of
atrial fibrillation, such as left atrial volume index, emptying fraction, expansion index, and
contractile function, may also be affected by height and may better explain the association
between height and atrial fibrillation.[38] Similarly, two-dimensional echocardiography
significantly underestimates left atrial size compared to MRI assessment.[39] Investigation of
these factors in the two-sample setting is limited by the lack of genetic studies of cardiac
structure/function by echocardiography, MRI, or cardiac CT, and study of these parameters in
large cohorts with genetics and imaging data is warranted.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Mendelian randomization has previously identified an association between shorter
stature and increased risk of coronary artery disease, mediated in part by increases in LDL
cholesterol and triglyceride levels.[10] In the current analysis, we were unable to detect
significant associations between these lipid traits and risk of atrial fibrillation when considered
in multivariable models alongside height. Similarly, in multivariable models considering height
alongside common cardiometabolic risk factors for atrial fibrillation, effect estimates were all
similar, suggesting these factors may not substantially mediate the effect of height on risk of
atrial fibrillation.
Although we detected no evidence of horizontal pleiotropy and our results remained
robust to extensive sensitivity analyses, height is a highly polygenic trait, and the possibility
remains that pleiotropic pathways mediate the association between height and atrial
fibrillation. A recent genome wide association study found genes at atrial fibrillation-associated
loci to be enriched in pathways important for tissue formation.[40] Coupled with the finding
that genes at height-associated loci are enriched for cardiovascular and endocrine tissue types,
these results raise the possibility of a more complex shared genetic architecture affecting both
height and atrial fibrillation.[22] Thus, we cannot exclude the possibility that genetic variants
broadly associated with growth and development may simultaneously affect height and
establish structural cardiovascular changes that may predispose to atrial fibrillation.
Our study has several limitations. First, observational analyses from the Penn Medicine
Biobank may not be generalizable, as this population represents a cohort within a single
academic health system. Second, despite our use of multiethnic GWAS of height and atrial
fibrillation, the underlying studies focused primarily on individuals of European ancestry.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Genetic studies in broader populations are warranted to further improve generalizability of
these findings. Third, our population-level MR analyses relied on publicly available summary
statistics which contain some overlapping samples/cohorts. Two-sample MR tends to bias the
causal effect estimates to the null, but sample overlap may make the estimate susceptible to
weak-instrument bias. In this study, however, despite overlapping cohorts, simulation suggests
the large sample sizes of the height and atrial fibrillation GWAS, and large F-statistics make the
risk of weak instrument bias low.[33]
In conclusion, we find that increases in height are associated with increased risk of atrial
fibrillation, and this relationship is likely to be causal. These results raise the possibility of
investigating height/growth-related pathways as a means for gaining novel mechanistic insights
to atrial fibrillation, as well as the possibility of incorporating height into larger targeted
screening strategies for atrial fibrillation.

FUNDING
This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases
R01-DK101478 and a Linda Pechenik Montague Investigator Award (BFV). SMD was supported
by the US Department of Veterans Affairs (IK2-CX001780). This publication does not represent
the views of the Department of Veterans Affairs or the United States government. DG was
supported by funding from the Wellcome Trust. Genetic sequencing of Penn Medicine Biobank
participants was performed in collaboration with Regeneron Genetics Center.

ACKNOWLEDGEMENTS

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

The authors would like to thank the participants of the Penn Medicine Biobank.

ETHICAL APPROVAL
The Penn Medicine Biobank has received approval from the University of Pennsylvania
Institutional Review Board. No additional approval was required for analyses of publicly
available summary statistics.

DATA SHARING
GWAS summary statistics for height GWAS can be downloaded from the GIANT consortium
website
(https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_file
s). Summary statistics for atrial fibrillation were contributed by the AFGen consortium
(http://afgen.org) and downloaded from the Variant to Function Knowledge Portal
(http://www.kp4cd.org/datasets/v2f). The data, analytic methods, and study materials may be
made available to other researchers for purposes of reproducing the results or replicating the
procedure upon reasonable request to the corresponding author and with the appropriate
ethical approval and data sharing agreements.

TRANSPARENCY
The lead author (MGL) affirms that the manuscript is an honest, accurate, and transparent
account of the study being reported; that no important aspects of the study have been omitted;

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

and that any discrepancies from the study as originally planned (and, if relevant, registered)
have been explained.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

REFERENCES
1

Chugh SS, Roth GA, Gillum RF, et al. Global burden of atrial fibrillation in developed and
developing nations. Glob. Heart. 2014;9:113â€“9. doi:10.1016/j.gheart.2014.01.004

2

January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management
of Patients With Atrial Fibrillation. J Am Coll Cardiol Published Online First: 2014.
doi:10.1016/j.jacc.2014.03.022

3

Tikkanen E, Gustafsson S, Ingelsson E. Associations of Fitness, Physical Activity, Strength,
and Genetic Risk With Cardiovascular Disease: Longitudinal Analyses in the UK Biobank
Study. Circulation 2018;:CIRCULATIONAHA.117.032432.
doi:10.1161/CIRCULATIONAHA.117.032432

4

Crump C, Sundquist J, Winkleby MA, et al. Height, Weight, and Aerobic Fitness Level in
Relation to the Risk of Atrial Fibrillation. Am J Epidemiol 2018;187:417â€“26.
doi:10.1093/aje/kwx255

5

Fenger-GrÃ¸n M, Overvad K, TjÃ¸nneland A, et al. Lean Body Mass Is the Predominant
Anthropometric Risk Factor for Atrial Fibrillation. J Am Coll Cardiol 2017;69:2488â€“97.
doi:10.1016/J.JACC.2017.03.558

6

Choi SH, Weng L-C, Roselli C, et al. Association Between Titin Loss-of-Function Variants
and Early-Onset Atrial Fibrillation. J Am Med Assoc 2018;320:1â€“11.
doi:10.1001/jama.2018.18179

7

Roselli C, Chaffin MD, Weng L-C, et al. Multi-ethnic genome-wide association study for
atrial fibrillation. Nat Genet Published Online First: 2018. doi:10.1038/s41588-018-01339

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

8

Nielsen JB, Thorolfsdottir RB, Fritsche LG, et al. Biobank-driven genomic discovery yields
new insight into atrial fibrillation biology. Nat. Genet. 2018;50:1234â€“9.
doi:10.1038/s41588-018-0171-3

9

Lai FY, Nath M, Hamby SE, et al. Adult height and risk of 50 diseases: a combined
epidemiological and genetic analysis. BMC Med 2018;16:187. doi:10.1186/s12916-0181175-7

10

Nelson CP, Hamby SE, Saleheen D, et al. Genetically Determined Height and Coronary
Artery Disease. N Engl J Med 2015;372:1608â€“18. doi:10.1056/NEJMoa1404881

11

Marott JL, Skielboe AK, Dixen U, et al. Increasing population height and risk of incident
atrial fibrillation: the Copenhagen City Heart Study. Eur Heart J Published Online First:
2018. doi:10.1093/eurheartj/ehy367

12

Siscovick DS, Ix JH, Gottdiener JS, et al. Measures of Body Size and Composition and Risk
of Incident Atrial Fibrillation in Older People: The Cardiovascular Health Study. Am J
Epidemiol 2016;183:998â€“1007. doi:10.1093/aje/kwv278

13

Schmidt M, BÃ¸tker HE, Pedersen L, et al. Adult height and risk of ischemic heart disease,
atrial fibrillation, stroke, venous thromboembolism, and premature death: A population
based 36-year follow-up study. Eur J Epidemiol Published Online First: 2014.
doi:10.1007/s10654-013-9867-y

14

Chang JD, Zimetbaum PJ, Rosenberg MA, et al. The impact of height on the risk of atrial
fibrillation: the Cardiovascular Health Study. Eur Heart J 2012;33:2709â€“17.
doi:10.1093/eurheartj/ehs301

15

Suzuki S, Yamashita T, Ohtsuka T, et al. Body Size and Atrial Fibrillation in Japanese

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Outpatients. Circ J Published Online First: 2010. doi:10.1253/circj.CJ-09-0431
16

Rosengren A, Hauptman PJ, Lappas G, et al. Big men and atrial fibrillation: Effects of body
size and weight gain on risk of atrial fibrillation in men. Eur Heart J Published Online First:
2009. doi:10.1093/eurheartj/ehp076

17

Mont L, Tamborero D, Elosua R, et al. Physical activity, height, and left atrial size are
independent risk factors for lone atrial fibrillation in middle-aged healthy individuals.
Europace Published Online First: 2008. doi:10.1093/europace/eum263

18

Hanna IR, Heeke B, Bush H, et al. The Relationship Between Stature and the Prevalence
of Atrial Fibrillation in Patients With Left Ventricular Dysfunction. J Am Coll Cardiol
2006;47:1683â€“8. doi:10.1016/j.jacc.2005.11.068

19

Yengo L, Sidorenko J, Kemper KE, et al. Meta-analysis of genome-wide association studies
for height and body mass index in ~700,000 individuals of European ancestry. bioRxiv
2018;:274654. doi:10.1101/274654

20

Yang J, Bakshi A, Zhu Z, et al. Genetic variance estimation with imputed variants finds
negligible missing heritability for human height and body mass index. Nat Genet
2015;47:1114â€“20. doi:10.1038/ng.3390

21

Yang J, Zeng J, Goddard ME, et al. Concepts, estimation and interpretation of SNP-based
heritability. Nat Genet 2017;49:1304â€“10. doi:10.1038/ng.3941

22

Wood AR, Esko T, Yang J, et al. Defining the role of common variation in the genomic and
biological architecture of adult human height. Nat Genet 2014;46:1173â€“86.
doi:10.1038/ng.3097

23

Hemani G, Zheng J, Elsworth B, et al. The MR-base platform supports systematic causal

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

inference across the human phenome. Elife Published Online First: 2018.
doi:10.7554/eLife.34408
24

Verbanck M, Chen C-Y, Neale B, et al. Detection of widespread horizontal pleiotropy in
causal relationships inferred from Mendelian randomization between complex traits and
diseases. Nat Genet Published Online First: 2018. doi:10.1101/157552

25

Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with
lipid levels. Nat Genet Published Online First: 2013. doi:10.1038/ng.2797

26

Shungin D, Winkler T, Croteau-Chonka DC, et al. New genetic loci link adipose and insulin
biology to body fat distribution. Nature 2015;518:187â€“96. doi:10.1038/nature14132

27

DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, Asian Genetic
Epidemiology Network Type 2 Diabetes (AGEN-T2D) Consortium, South Asian Type 2
Diabetes (SAT2D) Consortium, et al. Genome-wide trans-ancestry meta-analysis provides
insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet
2014;46:234â€“44. doi:10.1038/ng.2897

28

Dupuis J, Langenberg C, Prokopenko I, et al. New genetic loci implicated in fasting
glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010;42:105â€“
16. doi:10.1038/ng.520

29

Palmer TM, Lawlor DA, Harbord RM, et al. Using multiple genetic variants as
instrumental variables for modifiable risk factors. Stat Methods Med Res 2012;21:223â€“
42. doi:10.1177/0962280210394459

30

Holmes M V., Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids
for coronary heart disease. Eur Heart J 2015;36:539â€“50. doi:10.1093/eurheartj/eht571

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

31

Carroll RJ, Bastarache L, Denny JC. R PheWAS: Data analysis and plotting tools for
phenome-wide association studies in the R environment. Bioinformatics 2014;30:2375â€“6.
doi:10.1093/bioinformatics/btu197

32

R Development Core Team R, R Core Team. R: A language and environment for statistical
computing. R A Lang Environ Stat Comput Published Online First: 2017.
doi:10.1016/j.jssas.2015.06.002

33

Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample
Mendelian randomization. Genet Epidemiol 2016;40:597â€“608. doi:10.1002/gepi.21998

34

Johnson LSB, Salonen M, Kajantie E, et al. Early Life Risk Factors for Incident Atrial
Fibrillation in the Helsinki Birth Cohort Study. J Am Heart Assoc 2017;6.
doi:10.1161/JAHA.117.006036

35

Pritchett AM, Jacobsen SJ, Mahoney DW, et al. Left atrial volume as an index of left atrial
size: a population-based study. J Am Coll Cardiol 2003;41:1036â€“43. doi:10.1016/s07351097(02)02981-9

36

Leung DY, Chi C, Allman C, et al. Prognostic Implications of Left Atrial Volume Index in
Patients in Sinus Rhythm. Am J Cardiol 2010;105:1635â€“9.
doi:10.1016/j.amjcard.2010.01.027

37

Mont L, Tamborero D, Elosua R, et al. Physical activity, height, and left atrial size are
independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. EP
Eur 2008;10:15â€“20. doi:10.1093/europace/eum263

38

Gupta DK, Shah AM, Giugliano RP, et al. Left atrial structure and function in atrial
fibrillation: ENGAGE AF-TIMI 48. Eur Heart J 2014;35:1457â€“65.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

doi:10.1093/eurheartj/eht500
39

Rodevand O, Bjornerheim R, Ljosland M, et al. Left atrial volumes assessed by three- and
two-dimensional echocardiography compared to MRI estimates. Int J Card Imaging
1999;15:397â€“410. doi:10.1023/A:1006276513186

40

Nielsen JB, Fritsche LG, Zhou W, et al. Genome-wide Study of Atrial Fibrillation Identifies
Seven Risk Loci and Highlights Biological Pathways and Regulatory Elements Involved in
Cardiac Development. Am J Hum Genet 2018;102:103â€“15.
doi:10.1016/j.ajhg.2017.12.003

41

Dewey FE, Murray MF, Overton JD, et al. Distribution and clinical impact of functional
variants in 50,726 whole-exome sequences from the DiscovEHR study. Science (80- )
Published Online First: 2016. doi:10.1126/science.aaf6814

42

Chang CC, Chow CC, Tellier LCAM, et al. Second-generation PLINK: Rising to the challenge
of larger and richer datasets. Gigascience 2015;4. doi:10.1186/s13742-015-0047-8

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1: Demographics
No Atrial Fibrillation
(N = 3,803)

Atrial Fibrillation
(N = 3,220)

P-value

61.0 (53.0, 68.0)

65.0 (58.0, 74.0)

P < 0.001

2,110 (55)

2,230 (69)

P < 0.001

n; Median (IQR)
Height (in)

3,598; 28.0 (24.0, 32.0)

3,180; 28.0 (25.0, 32.0)

P < 0.001

n; Median (IQR)
Weight (lbs)

3,598; 67.0 (64.0, 70.0)

3,180; 69.0 (65.0, 71.5)

P < 0.001

Age
Median (IQR)
Male
n (%)
BMI (kg/m2)

n; Median (IQR)
3,598; 179.0 (150.0, 210.0)
Hypertension
n (%)
1,937 (51)
Coronary Artery Disease
n (%)
1,884 (50)
Heart Failure
n (%)
1,032 (27)
Hyperlipidemia
n (%)
1,991 (52)
Diabetes
n (%)
644 (17)
Chronic Kidney Disease
n (%)
434 (11)
Sleep Apnea
n (%)
441 (12)
Stroke
n (%)
615 (16)
Hyperthyroidism
n (%)
73 (2)
Cardiac Surgery
n (%)
881 (23)
Valve Disease
n (%)
978 (26)
Smoking (Ever)
n (%)
1,765/3,319 (53)

3,180; 189.5 (159.0, 222.0) P < 0.001
2,244 (70)

P < 0.001

1,902 (59)

P < 0.001

1,799 (56)

P < 0.001

2,078 (65)

P < 0.001

534 (17)

P = 0.701

622 (19)

P < 0.001

666 (21)

P < 0.001

769 (24)

P < 0.001

86 (3)

P = 0.036

2,180 (68)

P < 0.001

1,508 (47)

P < 0.001

1,621/2,899 (56)

P < 0.001

Demographics of individuals in Penn Medicine Biobank cohort with and without atrial
fibrillation. kg = kilograms, m = meters, in = inches, lbs = pounds.

FIGURE 1: Phenome-Wide Associations with Height and Height GRS

Phenome-wide association studies were performed in Penn Medicine Biobank participants to identify clinical phenotypes associated
with increased (A) height and (B) height GRS. The horizontal red line denotes the Bonferroni-adjusted level of significance
(0.05/1816 phenotypes), and triangles denote the direction of association between increasing height and risk of the phenotype
(point upward = increased risk; point downward = decreased risk).

medRxiv preprint doi: https://doi.org/10.1101/2019.12.23.19015743; this version posted December 30, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

FIGURE 2: Two-Sample Mendelian Randomization

Two-sample Mendelian randomization was performed using a genetic instrument containing
707 independent SNPs associated with height. A) Each point represents the SNP effects on
height and atrial fibrillation. Colored lines represent inverse variance weighted (red), weighted
median (green), and MR-Egger (blue) estimates of the association between a 1 standard
deviation increase in height and risk of atrial fibrillation. B) Odds Ratios (OR), 95% Confidence
Intervals (CI) and P-values for Mendelian randomization estimates.

FIGURE 3: Multivariable Mendelian Randomization Analysis

Multivariable Mendelian randomization was performed to jointly consider the effect of genetic variants for cardiometabolic traits
and height on atrial fibrillation. The dashed line at OR 1.34 represents the effect of height on atrial fibrillation observed in the
primary inverse variance weighted analysis. Odds Ratios (OR), 95% Confidence Intervals (CI) and P-values for Mendelian
randomization estimates are displayed.

FIGURE 4: Individual-Level Instrumental Variable Analysis

Individual-level instrumental variable analysis was performed in Penn Medicine Biobank participants, using a weighted genetic risk
score for height as an instrumental variable for measured height. The Base model was adjusted for age, sex, and 5 genetic principal
components. Model 1 additionally adjusted for weight, hypertension, coronary artery disease, heart failure, hyperlipidemia,
diabetes, chronic kidney disease, sleep apnea, stroke, hyperthyroidism, smoking, cardiac surgery, and valvular heart disease. Model
2 additionally adjusted for left atrial size as measured on transthoracic echocardiogram. Odds ratio are reported per 1 standard
deviation increase in height.

